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Scleroderma (SSc) is a complex and heterogeneous connective tissue disease mainly characterized by
autoimmunity, vascular damage, and fibrosis that mostly involve the skin and lungs. Epstein–Barr virus (EBV) is
a lymphotropic g-herpesvirus that has co-evolved with human species, infecting 495% of the adult population
worldwide, and has been a leading candidate in triggering several autoimmune diseases. Here we show that EBV
establishes infection in the majority of fibroblasts and endothelial cells in the skin of SSc patients, characterized
by the expression of the EBV noncoding small RNAs (EBERs) and the increased expression of immediate-early
lytic and latency mRNAs and proteins. We report that EBV is able to persistently infect human SSc fibroblasts
in vitro, inducing an aberrant innate immune response in infected cells. EBV–Toll-like receptor (TLR) aberrant
activation induces the expression of selected IFN-regulatory factors (IRFs), IFN-stimulated genes (ISGs),
transforming growth factor-b1 (TGFb1), and several markers of fibroblast activation, such as smooth muscle
actin and Endothelin-1, and all of these genes play a key role in determining the profibrotic phenotype in SSc
fibroblasts. These findings imply that EBV infection occurring in mesenchymal, endothelial, and immune cells of
SSc patients may underlie the main pathological features of SSc including autoimmunity, vasculopathy, and
fibrosis, and provide a unified disease mechanism represented by EBV reactivation.
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INTRODUCTION
Fibrosis is a pathologic scarring process that has been considered
the hallmark of systemic sclerosis (scleroderma (SSc)), a connective
tissue disease characterized by autoimmunity, inflammation, and
vasculopathy, leading to progressive fibrosis mostly of skin and
lungs. Fibroblasts, mainly myofibroblasts, clearly have a necessary
and fundamental role in promoting fibrosis (Varga and Abraham,
2007). Evidence suggests that innate immune activation of IFNs by
Toll-like receptors (TLRs) may play a role in the pathogenesis of
inflammation in many autoimmune diseases, initially assessed in
systemic lupus erythematous and more recently in SSc, implying
that dysregulation of the innate immune response underlies the
overactive immune system of individuals who are susceptible to
autoimmune disease (Theofilopoulos, 2012).
Recently, it has been shown by our group and by other
independent studies that IFN signature gene expression is
increased in peripheral blood mononuclear cells (PBMCs) and
in the skin of SSc patients (York et al., 2007; Farina et al.,
2010a). Furthermore, we showed that double-stranded RNA/
polyinosinic–polycytidylic acid, a TLR3 ligand, stimulates IFN
production, inflammation, and markers of vascular activation
in SSc skin (Farina et al., 2010b, 2011).
Although our studies strongly supported the potential key
role for double-stranded RNA/polyinosinic–polycytidylic acid
to contribute to innate immune activation in SSc, the origin of
the innate immune dysregulation in SSc is unknown, and to
date there is no obvious evidence addressing any potential
exogenous/endogenous source of RNA that might represent a
TLR3 ligand in SSc skin. In order to address this question, we
asked whether viral RNAs could be detected in the skin and
serve as innate immune ligands in SSc. Previous studies in
animal models have shown that murine cytomegalovirus
infection in immunocompromised mice resembles the patho-
logical processes seen in autoimmune diseases, particularly in
SSc, suggesting a link between herpesvirus infection and the
development of fibrosis (Pandey and LeRoy, 1998). However,
no direct evidence of cytomegalovirus infection, such as the
presence of viral protein or production of viral progeny, has
yet been found in SSc. As herpesvirus family has been linked to
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the development of fibrosis, we focused our attention on
Epstein–Barr virus (EBV), a g-herpesvirus that has been a leading
candidate in triggering several autoimmune diseases (Ebrahimi
et al., 2001; Niller et al., 2008; Dreyfus, 2011; Stoolman et al.,
2011). This virus is a biologically plausible source for
endogenous innate immune activation as it is ubiquitous in
nature, establishes a life-long silent infection with continuous
virus production because of reactivation, and most importantly,
modulates the human immune system, evolving immune
evasion strategies to the host antiviral response (Young and
Rickinson, 2004; Munz et al., 2009; Martorelli et al., 2012).
We show that EBV is able to infect human dermal
fibroblasts, and modulate the innate immune response in
infected fibroblasts, inducing fibroblast–myofibroblast conver-
sion typical of a profibrotic phenotype. We further demon-
strate the presence of EBV viral transcripts and proteins in the
majority of fibroblasts and endothelial cells in the skin of SSc
patients, supporting a crucial role of EBV in SSc pathogenesis.
Viral infection of nonimmune cells might provide a persistent
source of tissue injury and induce chronic inflammation and
fibrosis in SSc skin.
RESULTS
EBV transcripts are present in skin and in PBMCs from SSc
patients
The EBV noncoding RNA, EBV small RNA (EBER) is the most
abundant viral transcript in latently infected cells, and can
activate TLR3 and retinoic acid-inducible gene 1 (RIG-I)
(Samanta et al., 2008; Iwakiri et al., 2009). We investigated
EBER (EBER1/EBER2) expression in SSc skin by ‘‘in situ’’
hybridization in sections from representative SSc patients
(demographics and clinical characteristics are specified in
Supplementary Tables S1 and S2 online). We found a striking
accumulation of EBER-positive cells (EBERþ cells) in the deep
dermis of lesional/forearm (LdSSc) and nonlesional/back
(NLdSSc) SSc skin (Figure 1a and c). EBERþ cells were
distributed among the bundles of the extracellular matrix in
the deep dermis, showing spindle morphology and identified
as fibroblasts by the shape and location. The EBER signal was
mostly detected in cell nuclei, although certain nuclei of those
cells appear mostly destroyed and disintegrated (Figure 1a).
No EBERþ cells were detected in healthy donor (HD) skin
(Figure 1d, Supplementary Table S2 online). As myofibroblasts
play a pivotal role in fibrotic SSc skin, we asked whether
EBERþ cells may express smooth muscle actin (SMA), a
marker for myofibroblasts. Immunohistochemical staining of
serial skin biopsies showed that most, but not all SMA-stained
cells, colocalized with EBERþ cells (Figure 1e and f),
Interestingly EBERþ cells were also detected around blood
vessels, identified as smooth muscle cells by SMA immuno-
histochemical staining (Figure 1f, lower panels). We also
observed EBERþ cells in the myoepithelial layer of the
cutaneous glands (Figure 1g), as well as in most of the
endothelial cells in dermal ectatic vessels (Figure 1c). No
EBER staining was detected in smooth muscle cells and
myoepithelial or endothelial cells from HDs (Supplementary
Figure S1 online). EBERþ fibroblasts were also found in
patients with limited SSc (data not shown).
It is known that in B cells, detection of EBV DNA and EBER
or lytic RNAs/proteins identifies latent or active infection,
respectively (Okano et al., 2005). Thus, we asked whether
EBV infection is associated with expression of lytic or latency
genes in SSc skin. We found mRNA expression of both BZLF1,
the viral transactivator that drives EBV reactivation, switching
from latency to the lytic replication, and EBNA1, one of the
nine latency genes, present in LdSSc skin (Supplementary
Figure S2a online). Complementary DNA sequencing con-
firmed BZLF1 and EBNA1 specificity of the reverse
transcriptase–PCR products (data not shown). BZLF1 was also
detected in NLdSSc and in none of the control skin (Supple-
mentary Figure S2b online and Supplementary Table S2 online).
As EBV persists in B cells, we also investigated the state of
EBV infection in SSc PBMCs. We found that BZLF1 gene and
lytic and latency proteins were significantly increased in
PBMCs from SSc patients (Supplementary Figure S2c online
and Supplementary Tables S2 and S7 online). Although all the
patients and HDs were seropositive for EBV, a striking
increased production of antibodies against EBV viral capsid
antigen, the marker of acute EBV infection, was detected in
SSc sera (Supplementary Tables S1 and S3 online).
EBV DNA is detected in the skin of SSc patients
To further confirm the presence of EBV infection in SSc skin,
we measured EBV genome DNA. We found EBV EBER1 in
LdSSc (Supplementary Figure S2d online) and NLdSSc skin but
rarely in HD skin (Supplementary Table S2 online). DNA
sequencing confirmed that amplified DNA was indeed EBER1
(data not shown). Increased copies of EBV DNA were found in
LdSSc compared with HD skin (Supplementary Figure S2e
online). As it has been shown that most of the immunosup-
pressive medications used to treat organ transplant recipients
elevate EBV load and reactivate lytic/latency genes as has also
been shown in patients with systemic lupus erythematous or
other autoimmune disease, we selected a group of SSc patients
naive for any treatment compared with SSc patients who
received immunosuppressive therapy (Green et al., 2000;
Larsen et al., 2011). We found no statistical differences in
EBV DNA viral load (EBER1) and EBER expression in the skin
of the treatment-naive SSc patients compared with the
treated group (Supplementary Figures S2f and S4a–c online
and Supplementary Tables S4 and S5 online). Undetectable
levels of EBV DNA were measured in the skin from foreskin
samples as well as in 293 cells as negative control.
Assessment of viral proteins in SSc skin
We next investigated whether EBV transcripts might produce
viral proteins in SSc skin. Comparable to data obtained with
EBV transcripts, we found that the majority of the SSc patients
positive for EBV mRNA showed expression of lytic as well as
latent proteins in the skin (Supplementary Figure S3a–f online
and Supplementary Tables S6 and S7 online). It is noteworthy
that no lymphocyte infiltration was observed in areas where
ZEBRA-positive cells were detected. Nuclei of endothelial
cells and smooth muscle cells were also positive for BFLF2
and ZEBRA (Supplementary Figure S3c online). No difference
in ZEBRA protein skin expression was observed between
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biopsies from patient’s naive to immunosuppressed treatment
and biopsies from patients treated with immunosuppression
(Supplementary Figure S4d–f online). Notably, we did not find
expression of the late/EBV protein gp350/220 (Supplementary
Figure S5 online), or detection of mature virus production by
electron microscopy in SSc skin (data not shown), suggesting
that the virus lytic cycle is abortive (Martel-Renoir et al.,
1995). None of the HD skin sections showed specific staining
for ZEBRA and BFLF2 (Supplementary Figure S5 online).
EBV infects human SSc fibroblasts in vitro
EBV mainly infects B lymphocytes through CD21 receptor,
although it is generally accepted that it also infects epithelial
cells, even though they are CD21 negative. Thus, its presence
in fibroblasts was unexpected. No expression of EBV DNA,
mRNA, and/or protein was detected in primary fibroblast cell
lines. The first attempt of using cell-free EBV or recombinant
EBV p2089 (EBV-p2089) failed to infect any fibroblast cell
lines and it prompted us to explore how the virus gains access
into fibroblasts. As monocytes (MOs) have been found to be
increased in the perivascular areas of SSc skin, we used
purified MOs or dendritic cells (DCs) from HDs bound with
EBV-p2089 to perform transfer infection, as indicated by
previous reports using resting B cells as a transfer vehicle for
EBV infection of epithelial cells (Shannon-Lowe et al.,
2006; Feederle et al., 2007; York et al., 2007). MO or
DC virus-binding efficiency was detected by indirect
immunofluorescence assay using EBV anti-capsid antibody
(10–20% of MOs or DCs were able to bind the virus;
Figure 2a). No EBV infection was detected in MO/DCs
recovered after fibroblast transfer infection. After the transfer
infection, 10% cell/field of SSc fibroblasts showed nuclear
p2089–green fluorescent protein fluorescence at 5 days and 4
weeks after infection, respectively (Figure 2b and c and
Supplementary Figure S6a online). As fibroblasts do not
represent the natural target of EBV, we analyzed the expres-
sion of latency as well as lytic proteins in order to identify the
viral strategy in this EBV-infected cell type. EBV lytic proteins,
BFLF2/BFRF1, and latent antigen/EBNA2 were expressed at 4
weeks after infection in the nuclei of infected SSc cells defined
as fibroblasts by collagen-1 and collagen-11 staining and by
shape (Figure 2d–f and data not shown). We did not find the
expression of late lytic gene/BLLF1, suggesting that abortive
EBV replication occurs in EBV-infected SSc fibroblasts (data
not shown). We did not find any cleavage of poly (ADP-
ribose) polymerase protein in EBV-p2089 compared with
mock-infected SSc fibroblasts, confirming that EBV does not
induce apoptosis in infected SSc cells, as well as in infected B
cells (Supplementary Figure S6b online).
MO/DCs derived from different HDs consistently infected
all SSc fibroblast cell lines included in this study. Infected SSc
fibroblast cultures were monitored by indirect immunofluor-
escence assay. Fibroblasts from NLdSSc and from HDs were
also occasionally infected (ratio of 1 of 4). EBV-p2089
DNA persisted up to 6 months in infected LdSSc fibroblasts,
whereas EBV-p2089-infected NLdSSc fibroblasts and EBV-
p2089-infected HD fibroblasts died after 20 days after
infection.
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Figure 1. The Epstein–Barr virus (EBV)–encoded RNA (EBER)–infected cells in scleroderma (SSc) skin. (a–c) Representative images of in situ hybridization
(ISH) in lesional (LdSSc-1) and in nonlesional diffuse skin (NLdSSc-1) (a) showing EBERþ spindle cells in the deep dermis; (b) EBER staining in LdSSc-1 skin with
probe control; (c) EBER staining in endothelial cells of ectatic vessels in the skin (arrowhead); (d) EBER staining of healthy donor (HD) skin; (upper panels
bar¼ 100mm, lower panels 50mm). (e, f, upper panel) Colocalization of EBERþ cells detected by ISH (blue) with a-smooth muscle actin (aSMA) cells (red)
detected by immunohistochemical staining (IHC) in serial LdSSc skin sections (bar¼ 100mm and 50mm); (f, lower panel) EBERþ staining in blood vessels smooth
muscle cells identified by aSMA staining by IHC in serial skin section (arrows) (lower panel, bar¼ 50mm). (g) EBERþ cells detected in myoepithelial glands
surrounded by SMA fibers in skin (bar¼ 50mm).
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To exclude immune cell contamination in the fibro-
blast population, markers of MOs and DCs were evaluated
by semi-quantitative PCR. CD14 and BDCA1 mRNA
expression were undetectable in MOs, or DC transfer-infected
or mock-infected fibroblasts, although those markers were
expressed in MOs and DCs used as shuttle infection in
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Figure 2. In vitro infection of scleroderma (SSc) fibroblast. Monocytes (MOs) and dendritic cells (DCs) from healthy donors (HDs) previously exposed to
Epstein–Barr virus (EBV)-p2089 were co-cultured with SSc fibroblasts as described in the Materials and Methods. (a) Indirect immunofluorescence (IF) staining for EBV
gp350/220 antigen of MOs bound to EBV-p2089 (left panel: phase-contrast light microcopy, bar¼ 20mm). (b, c) Detection of EBV-p2089 green fluorescent protein
(GFP) in fibroblasts at 5 days (b) and 4 weeks (c) after infection (left panel: phase-contrast light microcopy, bar¼ 20mm). (d, e) Double IF of adherent or in suspension
fibroblasts (f) costained with the indicated antibodies at 4 weeks after infection (square insert, bar¼ 10mm). Diaminidino-2-phenylindole (DAPI) was used
as counterstaining for the nuclei. (g–i) mRNA expression of indicated genes in p2089 fibroblasts transfer-infected cultures, CD14þ /CD14 and BDCA1þ /BDCA1
population from HDs by semi-quantitative PCR. ctrl, control; fb, fibroblast; LMP1, latent membrane protein 1. Data are expressed as the fold change normalized to
mRNA expression in a single sample from HD. Bars represent mean±SEM *Po0.05; **Po0.01; ***Po0.001.
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fibroblast cultures (Figure 2g and h). Interestingly, latent
membrane protein 1 (LMP1) mRNA expression was found
significantly abundant in EBV-infected SSc cells, whereas no
LMP1 expression was detected in uninfected-, mock infected,
or MO/DCs from HDs, confirming that EBV is infecting
SSc fibroblasts (Figure 2i). Indirect immunofluorescence
assay staining for CD14/BDCA1 was absent in infected SSc
fibroblasts (data not shown).
EBV activates TLR pathway in infected SSc fibroblasts
To explore the interaction between EBV and fibroblast innate
immune responses, we examined the expression of TLR-
activated genes in infected cells at 4 weeks after infection.
Expression of TLR7 and TLR9 mRNA was significantly induced
in EBV/p2089-infected SSc fibroblasts (Figure 3a), as well as
the mRNA levels of IFN-regulatory factor 7 (IRF7), IRF5, and
IRF4, and selected IFN-stimulated genes (ISGs) (Figure 3a–c).
Remarkably, tumor necrosis factor-a, a gene found modulated
by EBV in B lymphocytes, was also robustly increased in EBV/
p2089-infected SSc fibroblasts. No increased expression of
TLRs, IRFs, or ISGs was observed in mock-infected or in
parallel uninfected fibroblast cultures.
EBV induces a profibrotic phenotype in infected SSc fibroblasts
Next we asked whether viral interaction with SSc fibroblasts
might also promote proliferation and expression of activation
markers as it does in B cells (Miller et al., 1972). Specifically,
we evaluated expression of genes and protein known to be
related to SSc profibrotic phenotype (Varga and Abraham,
2007). We found coexpression of EBV lytic protein BFRF1 and
SMA antigen in SSc fibroblasts, and increased expression of
genes implicated in fibroblast–myofibroblast conversion such
as transforming growth factor-b1 (TGFb1), endothelin 1
(EDN1), and SMA, and several TGFb-regulated genes (EGR1,
PAI1, COMP, and COLIV) in EBV/p2089-infected SSc fibro-
blasts at 4 weeks after infection (Figure 4a, b, and e and
Supplementary Figure S7 online). A persistent activation of
phospho-SMAD2, a critical mediator of TGFb-induced col-
lagen secretion, was also detected in the cell lysates of SSc
fibroblasts infected either by EBV/p2089 or EBV (Figure 4c).
TLR7 and TLR9 agonists stimulate IFN-regulated genes in
fibroblasts from healthy control skin
To evaluate whether activation of TLR7/TLR9 mimics the
innate immune modulation induced by EBV in infected SSc
fibroblasts, parallel fibroblast cultures generated from the
same SSc patients and HDs not exposed to the virus were
stimulated with TLR ligands, namely R837/imiquimod (for
TLR7) and CpGODN2006 oligonucleotide (for TLR9)
(Schoenemeyer et al., 2005; Paun et al., 2008).
We found that activation of the TLR pathway by
CpGODN2006, or a combination of R837 and CpGODN2006
ligands, significantly induced MX2, OAS2, and CXCL9 expres-
sion in HD fibroblasts 24 hours after treatment (Supplementary
Figure S8a online); chronic activation of TLR pathway induced
CXCL9 expression in HD fibroblasts treated for 4 weeks
(Supplementary Figure S9a online). No expression of TGFb-
regulated genes and/or increase of collagen secretion
were detected in acute/chronic TLR-stimulated HD fibroblasts
(Supplementary Figure S8c online and data not shown). In
contrast, we did not find activation of IFN-inducible gene
responses, as well as any increase of collagen secretion upon
acute/chronic stimulation by TLR7/9 ligand agonists in SSc
fibroblasts (Supplementary Figures S8b, d and S9b online).
DISCUSSION
We show here that EBV DNA, mRNAs, and proteins are present
in SSc skin, and the majority of the cells expressing EBER RNA
are fibroblasts. To investigate the consequences of EBV infec-
tion in stromal cells, we developed an innovative methodology
that requires MOs and DCs as a transfer vehicle for infection of
fibroblasts. Here, we report that EBV is able to infect human
fibroblasts ‘‘in vitro’’ and activate a fibroblast innate immune
response. Importantly, EBV infection of SSc fibroblasts promotes
the SSc profibrotic phenotype, inducing an aberrant TLR
activation pathway that is responsible for expression of IRFs,
selected ISGs, TGFb1, and several markers of fibroblast activa-
tion, such as SMA and Endothelin-1, in infected SSc cells. Our
study provides mechanistic insight into how EBV infection of
stromal cells affects fibroblast–myofibroblast conversion, which
is consistent with the phenotype seen in SSc skin.
EBV infection in LdSSc and in NLdSSc skin
We detected expression of the EBV transactivator BZLF1 gene,
latency genes, and early lytic protein in vivo in PBMCs, as
well as in the skin, indicating that EBV infection is systemic
and ongoing in SSc. Intriguingly, EBV expression of EBER,
BZLF1, and EBNA1, and EBV proteins for ZEBRA, BFRF1, and
BFLF2, were expressed in LdSSc and prominently in NLdSSc,
suggesting that a similar ‘‘EBV footprint’’ was found in areas
not associated with fibrosis. Previous studies have shown
almost identical disease-specific patterns of gene expression
from LdSSc, NLdSSc skin biopsies, and from fibroblast cul-
tures, revealing that both LdSSc and NLdSSc shared the same
gene expression (Whitfield et al., 2003; Fuzii et al., 2008); our
findings of EBV transcriptional programs in SSc skin are in line
with these data. As the mechanism of how the virus persists in
certain infected cells and not in others is still not clear, a
possible explanation would be that the innate immune system
of infected cells does not allow EBV to survive in the context
of NLdSSc skin.
Moreover, in SSc skin biopsies we found that smooth
muscle cells, myoepithelial cells, and most of the endothelial
cells expressed EBER RNA, suggesting that EBV tropism in vivo
could be broader than initially thought and extended to other
cell types as permissive targets in SSc.
EBV and innate immunity
EBV has long been proposed as a common associated factor
for autoimmune diseases: systemic lupus erythematous, rheu-
matoid arthritis, and multiple sclerosis, as EBV latent antigens
and high titers of EBV antibodies have been detected more
often in these patients; moreover, high titers of IgM viral
capsid antigen antibodies were found in SSc, implying a
recent EBV infection in this disease (Lunemann and Munz,
2007; Niller et al., 2008; Arnson et al., 2009). In support of
A Farina et al.
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this association, LMP1 antigen mRNA was detected in SSc
skin; however; the cellular source of the EBV product was not
identified (Vaughan et al., 2000). We show here that EBV early
lytic infection occurs in fibroblasts of SSc patients, suggesting
that fibroblasts might represent the crucial target of EBV
infection in SSc skin.
Several mechanisms have been described to explain how
EBV triggers autoimmune disease, such as antigen cross-
reactivity with self-nuclei protein and/or bystander activation
of autoreactive cells (Langland et al., 2006; Samanta et al.,
2008; Iwakiri et al., 2009; Munz et al., 2009). In this study we
reveal an unreported feature employed by EBV that involves
viral RNA and DNA triggering the innate immune system of
nonimmune cells. Specifically, we show that EBV triggers the
innate immune system activating TLR-like antiviral responses.
The contribution of EBV infection to the innate immune
system is unexplored in fibroblasts. EBV activates TLR7 in B
cells although additional mechanisms have recently been
proposed to explain how EBV might activate TLRs or
different pattern recognition receptors in other cellular
systems (Lindhout et al., 1994; Martin et al., 2007; Samanta
et al., 2008). We found that EBV increases mRNA levels of
IRF5/IRF7 and TLR7/9, suggesting that EBV might signal
through the TLR7/9-pathway in infected fibroblasts; however,
further experiments are required to address this issue. Several
studies showed that IRF5 and IRF7 are critical mediators of
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Figure 3. Epstein–Barr virus (EBV) activates innate antiviral response in infected scleroderma (SSc) fibroblasts. Monocytes (MOs) and dendritic cells (DCs) from
healthy donors (HDs) bound to EBV-p2089 were co-cultured with dermal fibroblasts from SSc patients. MOs and DCs not exposed to EBV-p2089 were co-cultured
with SSc fibroblasts as mock infection; fibroblasts left untreated were used as control (Ctrl). After 72 hours, MO, DCs, and EBV-p2089-free virus were removed from
fibroblasts cultures and total RNA extracted at 4 weeks after infection. (a–c) mRNA expression of Toll-like receptors (TLRs), IFN-regulatory factors (IRFs),
IFN-stimulated genes (ISGs), and tumor necrosis factor (TNF) in EBVp2089-infected, mock-infected, and control fibroblasts from SSc patients evaluated by
semi-quantitative PCR. Fold changes shown on the graph are normalized to mRNA expression by each corresponding untreated cell line. Bars represent
mean±SEM from five separate SSc fibroblast lines. P-values were calculated using two-tailed t-test *Po0.05; **Po0.01; ***Po0.001.
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TLR7/TLR9 signaling in response to single-stranded RNA
and CpG DNA in several cell types including fibroblasts
(Schoenemeyer et al., 2005; Tamura et al., 2008). Moreover,
IRF5 and IRF7 seem to be equally required by the host and the
virus, as both are crucial for the host in activating the IFN
system and for the virus in regulating several EBV proteins
necessary for viral B-cell transformation in infected cells (Ning
et al., 2003; Ning et al., 2005; Paun and Pitha, 2007; Savitsky
et al., 2010; Barton et al., 2011).
ISGs, TGFb, and EBV
We found that activation of TLR signaling by EBV promotes
fibroblast antiviral response that culminate with the induc-
tion of selected ISGs and TGFb-regulated genes that have
been found to be increased in PBMCs (tumor necrosis
factor-a, CXCL9, OAS2) and in the skin of patients with SSc
(CXCL9, OAS2, SMA, COMP, and EGR1) (Farina et al.,
2010b; Radstake et al., 2010). In addition, we also found
increased SMAD2 phosphorylation and collagen proteins
in EBV-infected SSc fibroblasts, suggesting that EBV directly
activates the TGFb transduction pathway. As expected, we
found that activation of TLR7/TLR9 by R837 and CpG-ODN
ligands significantly induced ISGs in HD fibroblasts (MX2,
IFI44, OAS2, CXCL9); nevertheless, none of these ligands
induced TGFb-regulated genes and collagen in HD
fibroblasts, suggesting that TLR activation in the absence
of chronic EBV infection is unable to stimulate a TGFb
response. Intriguingly, selected ISGs such as PKR, MX2,
and TLR3, which are transcriptionally regulated by type I
IFN, were not induced by the virus, suggesting that EBV
upregulates a distinct ‘‘IFN signature’’ incompetent to fully
stimulate the protective IFN response in infected SSc
fibroblasts. It is well accepted that EBV is a poor IFN
inducer permitting efficient lytic replication in B cells,
although the likelihood that it might happen in fibroblasts
is unexplored (Kikuta, 1986; Spender et al., 2001).
Specifically, EBV has evolved multiple strategies to evade
the immune system specifically suppressing and/or
blocking several pathways of the IFN response, mainly by
inhibiting IRF7 activity (Elia et al., 1996; Hahn et al., 2005;
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Langland et al., 2006; Wang et al., 2009; Wu et al., 2009;
Bentz et al., 2010; Michaud et al., 2010; Samanta and
Takada, 2010; Wang et al., 2011). Our data show that EBV
induces expression of IRF4 in infected fibroblasts,
suggesting that it might serve as a repressor of IFNa/b in
fibroblasts as it is known in immune cells (Hrdlickova et al.,
2001; Negishi et al., 2005; Paun and Pitha, 2007; Wang
et al., 2011).
EBV and fibroblast infection
Although fibroblasts are negative for the EBV receptor CD21,
spontaneous EBV fibroblast infection was detected in a
primary cell line from rheumatoid arthritis synovial tissue
(Koide et al., 1997). We did not detect EBV DNA in SSc
fibroblast cell lines (Figure 4d). Here we report a system that
successfully infects fibroblasts ‘‘in vitro,’’ providing evidence
that EBV is able to infect human dermal fibroblasts using MOs
or DCs as a vehicle for infection (Lindhout et al., 1994; Savard
et al., 2000). It is likely that EBV uses alternative strategies to
infect fibroblasts that bypass the absence of CD21, similar to
the described transmission of EBV to human epithelial cells by
cell-to-cell contact (Janz et al., 2000). There is a growing
interest in exosomes, the specialized membranous vesicles
derived from the endocytic compartment that can carry and
deliver functional mRNA, miRNAs, and proteins to various
cells (Valadi et al., 2007; Pegtel et al., 2010; Zomer et al.,
2010). Thousands of EBV miRNA copy numbers have been
detected in exosomes from lymphoblastoid cell line–infected
cells, suggesting that EBV-containing exosomes may be
continuously secreted and transferred from the infected cells
to uninfected neighboring cells (Pegtel et al., 2010; Wurdinger
et al., 2012). Possibly, EBV-infected immune cells might
transfer functional EBV RNA and protein to fibroblasts
through exosomes.
Our data show that EBV persists in fibroblasts exploiting
both lytic and latent cycles. We did not detect any late viral
product gp350/220 and/or mature virions in SSc biopsies,
suggesting that EBV replication is not complete in infected
SSc fibroblasts and possibly occurs in an abortive cycle,
whereas viral DNA might be conserved in growing fibroblast
cultures. Previous studies showed that the EBV lytic cycle is
abortive in several EBV-associated diseases and in specific
infected cells (Bibeau et al., 1994; Martel-Renoir et al., 1995;
Al Tabaa et al., 2009; Al Tabaa et al., 2011). Perhaps,
fibroblasts do not provide the necessary environment for
productive infection and hence the virus is not able to
perform the normal replication program.
EBV/p2089-recombinant and EBV/B95-8-cell-derived virus
show similar cellular tropism in infecting LdSSc, NLdSSc, and
HD fibroblasts ‘‘in vitro,’’ suggesting that EBV infection can
occur in mesenchymal cells. Intriguingly, we noticed that
LdSSc and to a lesser degree NLdSSc as well as HD fibroblast
lines could all be infected by EBV; however, only fibroblasts
from LdSSc and occasionally from NLdSSc skin were able to
support sustained viral presence for up to 6 months. These
results suggest that the LdSSc fibroblast phenotype might
predispose to EBV chronic infection, promoting EBV survival
in the cells, whereas fibroblasts from HDs appear to be able to
control EBV infection, clearing the virus. Possibly, EBV
infection spontaneously resolves in the context of presumably
immunocompetent condition. In our case infected cells from
HD might still have a competent immune system able to
induce a full IFN response controlling the EBV infection.
Characterization of ‘‘EBV-IFN-signature’’ deserves further
investigation specifically in these cells.
EBV and SSc profibrotic phenotype
Activated fibroblasts are considered the principal mediators of
fibrogenesis in SSc. It is known that SSc fibroblasts show a
profibrotic phenotype with sustained TGFb activation,
increased collagen production, and increased number of
myofibroblasts (Varga and Abraham, 2007). We found that
the EBV lytic cascade is associated with upregulation of
TGFb1, several TGFb-regulated genes, including SMA, and
increased collagen by infected fibroblasts. Intriguingly, the
EBV transactivator BZLF1 gene has been linked to
development of fibrosis in some other EBV-associated
diseases, although its primary role is to disrupt viral latency
and transactivate the expression of early lytic genes (Grogan
et al., 1987; Guenther et al., 2010). Specifically, BZLF1 was
shown to interact with numerous key cellular transcriptional
regulatory factors including TGFb1/3 and EGR1 in infected
epithelial cells (Cayrol and Flemington, 1995; Adamson and
Kenney, 1999; Chang et al., 2006; Tsai et al., 2009). Thus,
BZLF1 interaction with one of these factors might also be
responsible for SMAD2 phosphorylation and TGFb1 increased
expression in EBV-infected SSc fibroblasts.
Previous studies have suggested a role for EBV infection as
in the pathogenesis of smooth muscle tumors in patients with
clinical immunosuppression. Specifically, EBER was found
expressed in smooth muscle tumor cells and in myofibroblasts
from sclerosing nodular transformation of the spleen, suggest-
ing that EBV-infected myofibroblasts could be a common
pathway of a fibrosclerotic process occurring in splenic
inflammatory tumor-like lesion, although the origin of
EBERþ myofibroblasts was not fully understood (Lee et al.,
1995; Weinreb et al., 2007; Kashiwagi et al., 2008). Our
in vitro data showed that EBV induces a myofibroblast
phenotype in infected SSc fibroblasts.
Our results show that SSc fibroblasts have greatly dimin-
ished IFN-inducible gene response upon TLR7/9 agonist
stimulation, possibly one of the reasons that EBV is able to
infect and persist in SSc fibroblasts. Further experiments are
needed to understand whether EBV infection might induce
epigenetic changes in infected fibroblasts, as it does in B cells
and lymphoblastoid and epithelial cells, blunting the IFN
response in ‘‘transformed’’ cells (Gregorovic et al., 2011;
Banerjee et al., 2013; Queen et al., 2013).
Overall, our study provides compelling evidence that EBV
infection could contribute to fibrosis in SSc skin through
multiple factors and a combination of subsequent pathological
events such as virus host cellular interactions that may
lead to aberrant activation of TLR pathway in infected SSc
fibroblasts. This pathway activates selected ISGs and cyto-
kines and influences fibroblast profibrotic phenotype driving
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myofibroblast conversion. These results indicate that EBV
infection might cause the patho-immunogenetic alterations seen
in SSc fibroblasts, and those abnormalities are related to the
viral strategies that subvert the host innate immune response in
infected cells.
Concurrent EBV infection occurring in mesenchymal,
endothelial, and immune cells of SSc patients may underlay
the main pathological features of SSc including autoimmunity,
vasculopathy, and fibrosis, and provide a unified disease
mechanism represented by EBV reactivation.
MATERIALS AND METHODS
Study subjects
All study subjects met the criteria for SSc as defined previously (LeRoy
et al., 1988). The study was conducted under a protocol in adherence
to the Declaration of Helsinki Principles and approved by the Boston
University Medical Center, Institutional Review Board, and all subjects
gave written informed consent. Skin biopsies were performed as
previously described (Farina et al., 2010a,b)
EBER ‘‘in situ’’ hybridization
In situ hybridization for EBV-encoded RNA (EBER) was carried out
using FITC (FITC-l-labeled peptide nucleic acid probed for EBER and
peptide nucleic acid in situ hybridization detection kit (DAKO,
Carpinteria, CA)) on paraffin-embedded skin sections according to
the manufacturer’s protocol.
Virus preparation
EBV was obtained from producing-B95.8 cell line and from p2089 cell
line as previously described (Delecluse et al., 1998; Farina et al., 2000).
Isolation of MOs and monocyte-derived DCs from HDs
PBMCs from 10 HDs were isolated by Ficoll Paque gradient
centrifugation (Pharmacia, Uppsala, Sweden). CD14þ /monocytes
were positively selected using anti-CD14 mAb-conjugated magnetic
microbeads (Miltenyi Biotec, Auburn, CA) confirmed by flow cyto-
metry (Cirone et al., 2007). Each group of infection (n¼ 6) was carried
out using fibroblasts from SSc and HDs, and MOs/DCs from a
single HD at the time. MOs/DCs isolated from different HDs were
used to infect the same SSc fibroblast cell lines. CD14þ / and
BDCA1þ / selection markers were also evaluated by semi-
quantitative PCR.
Transfer infection
Donor cells (MOs and DCs) obtained from 10 HDs were exposed to
EBV and/or p2089 at known multiplicities of infection for 3 hours at
4 1C; after extensive washing, 104/cells were added to confluent
fibroblast culture in 8-well chamber slides (Feederle et al., 2007). At
72 hours after co-cultivation with human primary fibroblast,
supernatants (MOs/DCs) were removed and cultured separately
from the infected fibroblast. After 2 days, total RNA was extracted
from MOs and DCs. Transfer infection in fibroblasts cultures was
assayed 72 hours after the initiation of co-culture by counting the
percentage of green fluorescent protein–positive cells in trypsinized
acceptor cell suspensions. The p2089-infected, mock-infected, and
control fibroblasts were cultured in DMEM (10% fetal calf serum)
and monitored by indirect immunofluorescence assay or PCR
up to 6 months after infection. Total RNA was extracted from
p2089-infected-, mock-infected, and control SSc fibroblasts at 4
weeks after infection.
Statistical analyses
All data are expressed as mean±SE. The means between two groups
were analyzed by Student’s t-test, Wilcoxon test, and Fisher’s exact
test. Significance was taken at Po0.05.
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